retatrutide phase 2 trial type 2 diabetes weight loss 2024 Lilly's triple agonist, retatrutide, successful in two additional 3 obesity trials, delivering significant improvements in and A1C Retatrutide improves blood sugar and

If it works well enough, this would give doctors a lower-dose option for patients who respond without needing the maximum, similar to how many tirzepatide patients do well on 10 mg without going to 15 mg

While published subgroup analyses focus primarily on diabetes status rather than age categories, the available data allows for some preliminary observations about younger participants

All of the dynamics around GLP-1s, compounding shortage workarounds, and potential for DTC telehealth fallout I described last August seem to be playing out in 2025

Long-Term Outlook for Retatrutide Benefits Maintaining results requires ongoing commitment to healthy habits and potentially continued treatment